Saltar al contenido principal
xMedica

NCT07784725ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Fase 32500 participantes buscados220 centros16 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 212 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    212 sites

  • Country count15/15

    16 countries

  • Planned duration8/10

    Planned over about 34 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Afecciones

  • Obesity or Overweight

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseFase 3
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoQUADRUPLE (4)
Inscripción2500 participantes buscados

Patrocinador y colaboradores

  • AstraZeneca Patrocinador

Grupos e intervenciones

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Intervenciones

  • Fármaco Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Fármaco Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Variables de resultado

  1. Variable de resultado principal

    Percent change in body weight from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in percent body weight change

    Plazo 68 weeks

  2. Variable de resultado secundaria

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight

    Plazo 68 weeks

  3. Variable de resultado secundaria

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%

    Plazo 68 weeks

  4. Variable de resultado secundaria

    Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%

    Plazo 68 weeks

  5. Variable de resultado secundaria

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on waist circumference change

    Plazo 68 weeks

  6. Variable de resultado secundaria

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change

    Plazo 68 weeks

  7. Variable de resultado secundaria

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change

    Plazo 68 weeks

  8. Variable de resultado secundaria

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants

    Plazo 68 weeks

Fechas

Fechas
Fecha de inicio19 de agosto de 2026 (real)
Finalización principal11 de agosto de 2028 (estimada)
Finalización21 de mayo de 2029 (estimada)
Primera publicación25 de agosto de 2026 (real)
Última actualización30 de octubre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezoctubre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

76 centros están en reclutamiento

Argentina

Argentina
CentroCiudadEstado o regiónEstado
Research SiteBuenos AiresEn reclutamiento
Research SiteBuenos AiresEn reclutamiento
Research SiteCiudad de Buenos AiresEn reclutamiento
Research SiteMendozaEn reclutamiento
Research SiteRamos MejíaAún no recluta
Research SiteRosarioEn reclutamiento
Research SiteSan NicolásAún no recluta

Australia

Australia
CentroCiudadEstado o regiónEstado
Research SiteBotanyEn reclutamiento
Research SiteCamberwellEn reclutamiento
Research SiteCharlestownEn reclutamiento
Research SiteSt AlbansEn reclutamiento
Research SiteSt LeonardsEn reclutamiento
Research SiteWaitaraEn reclutamiento

Brazil

Brazil
CentroCiudadEstado o regiónEstado
Research SiteBelo HorizonteAún no recluta
Research SiteBrasíliaAún no recluta
Research SiteCampinasAún no recluta
Research SiteCampinasAún no recluta
Research SiteCuritibaRetirado
Research SiteCuritibaAún no recluta
Research SiteCuritibaAún no recluta
Research SiteNatalAún no recluta
Research SitePorto AlegreAún no recluta
Research SiteRio de JaneiroAún no recluta
Research SiteSão José dos CamposAún no recluta
Research SiteSão PauloAún no recluta

Bulgaria

Bulgaria
CentroCiudadEstado o regiónEstado
Research SiteMontanaAún no recluta
Research SitePlevenAún no recluta
Research SitePlovdivEn reclutamiento
Research SiteSofiaEn reclutamiento
Research SiteSofiaEn reclutamiento
Research SiteSofiaEn reclutamiento
Research SiteVarnaAún no recluta
Research SiteYambolEn reclutamiento

Canada

Canada
CentroCiudadEstado o regiónEstado
Research SiteBramptonOntarioEn reclutamiento
Research SiteCalgaryAlbertaEn reclutamiento
Research SiteGuelphOntarioEn reclutamiento
Research SiteHamiltonOntarioEn reclutamiento
Research SiteMississaugaOntarioEn reclutamiento
Research SiteMonctonNew BrunswickEn reclutamiento
Research SiteMontrealQuebecEn reclutamiento
Research SiteNew WestminsterBritish ColumbiaEn reclutamiento
Research SiteNorth YorkOntarioEn reclutamiento
Research SiteQuébecQuebecEn reclutamiento
Research SiteQuébecQuebecEn reclutamiento
Research SiteSaint-Charles-BorroméeQuebecEn reclutamiento
Research SiteScarborough VillageOntarioEn reclutamiento
Research SiteSherbrookeQuebecEn reclutamiento
Research SiteStoney CreekOntarioEn reclutamiento
Research SiteStouffvilleOntarioEn reclutamiento
Research SiteSurreyBritish ColumbiaRetirado

En el registro figuran 170 centros más.

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 30 de octubre de 2026

    Centro añadido

    8 sites added (220 total)

    212220